Literature DB >> 24890337

Albuminuria correlates with hemolysis and NAG and KIM-1 in patients with sickle cell anemia.

Dima Hamideh1, Vimal Raj, Thomas Harrington, Hua Li, Emilio Margolles, Folasade Amole, Monica Garcia-Buitrago, Phillip Ruiz, Gaston Zilleruelo, Ofelia Alvarez.   

Abstract

BACKGROUND: Although hyperfiltration and albuminuria are common pathological conditions, kidney injury (KI) biomarkers have been seldom studied in individuals with sickle cell anemia (SCA).
METHODS: We undertook a cross-sectional assessment of urine KI biomarkers in children and adults with SCA with and without albuminuria and a normal estimated glomerular filtration rate (eGFR). Albumin, KI molecule 1 (KIM-1), N-acetyl-ß-D-glucosaminidase (NAG), endothelin-1 and transforming growth factor-β1 (TGF-β1) were measured. Assays were normalized by urine creatinine. Urine intracellular hemosiderin and serum lactate dehydrogenase (LDH) were assessed as markers of hemolysis. Albuminuria was associated to the biomarkers by Pearson and Spearman correlation coefficients. Differences between the albuminuria (yes, no) groups were assessed by the t test.
RESULTS: Nineteen patients with albuminuria (mean urine albumin/creatinine 527.14 ± 1070 mg/g, range 38.3--190 mg/g) and 19 patients without albuminuria (mean urine albumin/creatinine 15.93 ± 5.17 mg/g, range 7.9-28.4 mg/g) were studied. The age range for the whole group was 11-48 years, and 47 % were males. Patients with albuminuria were older, had lower hematocrit, were more likely to test positive for urine hemosiderin and had a higher KIM-1 (P = 0.0035) and NAG/ creatinine ratios (P = 0.0062). Urine hemosiderin strongly correlated to a higher LDH level (P < 0.001).
CONCLUSIONS: Despite a normal or increased eGFR, KI biomarkers were detected in the urine of individuals with SCA. NAG, KIM-1 and urine hemosiderin correlated with the presence of albuminuria.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24890337     DOI: 10.1007/s00467-014-2821-8

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  47 in total

1.  Biomarkers for early detection of sickle nephropathy.

Authors:  Nambirajan Sundaram; Michael Bennett; Jamie Wilhelm; Mi-Ok Kim; George Atweh; Prasad Devarajan; Punam Malik
Journal:  Am J Hematol       Date:  2011-05-31       Impact factor: 10.047

2.  Urinary endothelin-1 as a marker of renal damage in sickle cell disease.

Authors:  Pierre-Louis Tharaux; Isabelle Hagège; Sandrine Placier; Michel Vayssairat; Alain Kanfer; Robert Girot; Jean-Claude Dussaule
Journal:  Nephrol Dial Transplant       Date:  2005-09-06       Impact factor: 5.992

3.  MYH9 and APOL1 are both associated with sickle cell disease nephropathy.

Authors:  Allison E Ashley-Koch; Emmanuel C Okocha; Melanie E Garrett; Karen Soldano; Laura M De Castro; Jude C Jonassaint; Eugene P Orringer; James R Eckman; Marilyn J Telen
Journal:  Br J Haematol       Date:  2011-09-13       Impact factor: 6.998

4.  Endothelin-1 increases collagen accumulation in renal mesangial cells by stimulating a chemokine and cytokine autocrine signaling loop.

Authors:  Michael S Simonson; Faramarz Ismail-Beigi
Journal:  J Biol Chem       Date:  2010-12-17       Impact factor: 5.157

5.  Early blood transfusions protect against microalbuminuria in children with sickle cell disease.

Authors:  Ofelia Alvarez; Brenda Montane; Gabriela Lopez; James Wilkinson; Tracie Miller
Journal:  Pediatr Blood Cancer       Date:  2006-07       Impact factor: 3.167

6.  Lactate dehydrogenase as a predictor of kidney involvement in patients with sickle cell anemia.

Authors:  Sevgi Gurkan; Kyla J Scarponi; Hilary Hotchkiss; Beth Savage; Richard Drachtman
Journal:  Pediatr Nephrol       Date:  2010-06-02       Impact factor: 3.714

Review 7.  Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes.

Authors:  Gregory J Kato; Mark T Gladwin; Martin H Steinberg
Journal:  Blood Rev       Date:  2006-11-07       Impact factor: 8.250

8.  Urinary biomarkers in the clinical prognosis and early detection of acute kidney injury.

Authors:  Jay L Koyner; Vishal S Vaidya; Michael R Bennett; Qing Ma; Elaine Worcester; Shahab A Akhter; Jai Raman; Valluvan Jeevanandam; Micheal F O'Connor; Prasad Devarajan; Joseph V Bonventre; Patrick T Murray
Journal:  Clin J Am Soc Nephrol       Date:  2010-08-26       Impact factor: 8.237

9.  Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies.

Authors:  Vishal S Vaidya; Josef S Ozer; Frank Dieterle; Fitz B Collings; Victoria Ramirez; Sean Troth; Nagaraja Muniappa; Douglas Thudium; David Gerhold; Daniel J Holder; Norma A Bobadilla; Estelle Marrer; Elias Perentes; André Cordier; Jacky Vonderscher; Gérard Maurer; Peter L Goering; Frank D Sistare; Joseph V Bonventre
Journal:  Nat Biotechnol       Date:  2010-05       Impact factor: 54.908

10.  Chronic renal failure in sickle cell disease: risk factors, clinical course, and mortality.

Authors:  D R Powars; D D Elliott-Mills; L Chan; J Niland; A L Hiti; L M Opas; C Johnson
Journal:  Ann Intern Med       Date:  1991-10-15       Impact factor: 25.391

View more
  16 in total

1.  Changes in Conjunctival Hemodynamics Predict Albuminuria in Sickle Cell Nephropathy.

Authors:  Ali Kord Valeshabad; Justin Wanek; Santosh L Saraf; Bruce I Gaynes; Victor R Gordeuk; Robert E Molokie; Mahnaz Shahidi
Journal:  Am J Nephrol       Date:  2015-08-05       Impact factor: 3.754

Review 2.  Sickle cell disease: renal manifestations and mechanisms.

Authors:  Karl A Nath; Robert P Hebbel
Journal:  Nat Rev Nephrol       Date:  2015-02-10       Impact factor: 28.314

3.  Heme A1M'ed at the kidney in sickle cell disease.

Authors:  Santosh L Saraf
Journal:  Blood       Date:  2020-03-26       Impact factor: 22.113

Review 4.  Intravascular hemolysis and the pathophysiology of sickle cell disease.

Authors:  Gregory J Kato; Martin H Steinberg; Mark T Gladwin
Journal:  J Clin Invest       Date:  2017-03-01       Impact factor: 14.808

5.  Renal protection by atorvastatin in a murine model of sickle cell nephropathy.

Authors:  Rima S Zahr; Prasanthi Chappa; Hong Yin; Lou A Brown; Kenneth I Ataga; David R Archer
Journal:  Br J Haematol       Date:  2018-03-12       Impact factor: 6.998

6.  End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings.

Authors:  Ann T Farrell; Julie Panepinto; Ankit A Desai; Adetola A Kassim; Jeffrey Lebensburger; Mark C Walters; Daniel E Bauer; Rae M Blaylark; Donna M DiMichele; Mark T Gladwin; Nancy S Green; Kathryn Hassell; Gregory J Kato; Elizabeth S Klings; Donald B Kohn; Lakshmanan Krishnamurti; Jane Little; Julie Makani; Punam Malik; Patrick T McGann; Caterina Minniti; Claudia R Morris; Isaac Odame; Patricia Ann Oneal; Rosanna Setse; Poornima Sharma; Shalini Shenoy
Journal:  Blood Adv       Date:  2019-12-10

Review 7.  The spectrum of sickle hemoglobin-related nephropathy: from sickle cell disease to sickle trait.

Authors:  Rakhi P Naik; Vimal K Derebail
Journal:  Expert Rev Hematol       Date:  2017-10-30       Impact factor: 2.929

8.  Progression of albuminuria in patients with sickle cell anemia: a multicenter, longitudinal study.

Authors:  Omar Niss; Adam Lane; Monika R Asnani; Marianne E Yee; Ashok Raj; Susan Creary; Courtney Fitzhugh; Prasad Bodas; Santosh L Saraf; Sharada Sarnaik; Prasad Devarajan; Punam Malik
Journal:  Blood Adv       Date:  2020-04-14

Review 9.  Sickle cell nephropathy: an update on pathophysiology, diagnosis, and treatment.

Authors:  Essa Hariri; Anthony Mansour; Andrew El Alam; Yazan Daaboul; Serge Korjian; Sola Aoun Bahous
Journal:  Int Urol Nephrol       Date:  2018-01-30       Impact factor: 2.370

10.  Hyperfiltration during early childhood precedes albuminuria in pediatric sickle cell nephropathy.

Authors:  Jeffrey D Lebensburger; Inmaculada Aban; Brandi Pernell; Malgorzata Kasztan; Daniel I Feig; Lee M Hilliard; David J Askenazi
Journal:  Am J Hematol       Date:  2019-01-08       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.